There are currently 443 clinical trials in Memphis, Tennessee looking for participants to engage in research studies. Trials are conducted at various facilities, including St. Jude Children's Research Hospital, Saint Jude Children's Research Hospital, Baptist Memorial Hospital and Cancer Center-Memphis and University of Tennessee Health Science Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Cost Communication and Financial Navigation in Cancer Patients (COSTCOM)
Recruiting
This clinical trial evaluates the effect of Cost Communication and Financial Navigation (CostCOM) intervention on adherence to care and financial burden in cancer patients. Many cancer patients experience financial hardship due to high medical out of pocket costs (OOPC), changes in employment, income and insurance. Financial hardship can lead to a delay or a stop in cancer care, and is linked to poor quality of life. Financial navigation programs, such as CostCOM, provide financial counseling, e... Read More
Gender:
ALL
Ages:
All
Trial Updated:
08/08/2024
Locations: Baptist Memorial Hospital and Cancer Center-Memphis, Memphis, Tennessee
Conditions: Malignant Solid Neoplasm
The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)
Recruiting
The purpose of the study is to evaluate the long term safety and efficacy of orally administered M5049 in participants with subacute cutaneous lupus erythematosus (SCLE), discoid lupus erythematosus (DLE) and/or systemic lupus erythematosus (SLE) who have completed the 24 week treatment period of Willow study (MS200569_0003 \[NCT05162586\]).
Gender:
ALL
Ages:
Between 18 years and 76 years
Trial Updated:
08/07/2024
Locations: Ramesh C Gupta, MD, Memphis, Tennessee
Conditions: Systemic Lupus Erythematosus
An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study
Recruiting
The purpose of this study is: * To investigate the optimal timing for revaccination after the initial RSVPreF3 OA vaccine dose, * To evaluate the long-term immune persistence and safety up to 5 consecutive RSV seasons (approximately 60 months) of a single dose of RSVPreF3 OA vaccine, * To give the opportunity to participants who received only placebo in the RSVOA=ADJ- 006 study, to receive a dose of the RSVPreF3 OA vaccine and collect additional safety information.
Gender:
ALL
Ages:
60 years and above
Trial Updated:
08/02/2024
Locations: GSK Investigational Site, Memphis, Tennessee
Conditions: Respiratory Syncytial Virus Infections
A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome
Recruiting
The purpose of this study is to evaluate the safety and efficacy of EPX-100 as adjunctive therapy in participants with Dravet syndrome.
Gender:
ALL
Ages:
2 years and above
Trial Updated:
08/02/2024
Locations: Le Bonheur Children's Hospital, Memphis, Tennessee
Conditions: Dravet Syndrome
Study of Stored Tumor Samples in Young Patients With Brain Tumors
Recruiting
This laboratory study is looking at stored tumor samples in young patients with brain tumors. Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
Gender:
ALL
Ages:
39 years and below
Trial Updated:
08/01/2024
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Brain and Central Nervous System Tumors
Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases
Recruiting
This phase II trial studies the effect of sacituzumab govitecan in treating patients with HER2-negative breast cancer that has spread to the brain (brain metastases). Sacituzumab govitecan is a monoclonal antibody, called sacituzumab, linked to a chemotherapy drug, called govitecan. Sacituzumab is a form of targeted therapy because it attaches to specific molecules on the surface of cancer cells, known as Trop-2 receptors, and delivers govitecan to kill them. Giving sacituzumab govitecan may shr... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/31/2024
Locations: Baptist Memorial Hospital and Cancer Center-Memphis, Memphis, Tennessee
Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic HER2 Negative Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Prognostic Stage IV Breast Cancer AJCC v8
Opioid Prescribing Practices in Laparoscopic Gynecologic Surgery
Recruiting
The purpose of this study is to compare opioid prescribing practices by either routine provider prescribing practices, or with the use of a calculator, i.e., the Opioid Calculator, published by the University of Michigan (www.opioidcalculator.org), with the intent of decreasing the number of pills.
Gender:
FEMALE
Ages:
Between 18 years and 80 years
Trial Updated:
07/31/2024
Locations: University of Tennessee Health Science Center, Memphis, Tennessee
Conditions: Opioid Use, Postoperative Pain
Clinical Study to Evaluate the Effects of Two Novel Hydration Beverage Formulas on Rehydration in Healthy Adults
Recruiting
The aim of the clinical trial is to evaluate the efficacy of two novel hydration products on rehydration following exercise.
Gender:
ALL
Ages:
Between 18 years and 35 years
Trial Updated:
07/26/2024
Locations: The University of Memphis, Memphis, Tennessee
Conditions: Dehydration, Rehydration, Exercise Performance, Exercise Recovery, Cognitive Performance
A Prospective Study to Observe & Describe Clinical Outcomes of Alglucosidase Alfa Treatment in Patients ≤6 Months of Age With Infantile-onset Pompe Disease (IOPD)
Recruiting
Primary Objective: To describe the effect of routine practice with alglucosidase alfa in patients with IOPD ≤6 months of age, on invasive ventilation-free survival after 52 weeks of treatment. Secondary Objectives: * To describe the effect of routine practice with alglucosidase alfa on invasive ventilation-free survival and survival at 12 and 18 months of age, as well as on change in left ventricular mass (LVM) Z score, Alberta Infant Motor Scale (AIMS) score, body weight, body length, and he... Read More
Gender:
ALL
Ages:
Between 0 days and 6 months
Trial Updated:
07/24/2024
Locations: Le Bonheur Children's Hospital Site Number : 8400005, Memphis, Tennessee
Conditions: Glycogen Storage Disease Type II
Pain With Differing Insufflation Pressures During Laparoscopic Hysterectomy
Recruiting
The purpose of this study is to determine the effect of decreased insufflation pressure on postoperative pain, analgesic use, and surgical safety and feasibility for laparoscopic hysterectomy.
Gender:
FEMALE
Ages:
Between 18 years and 80 years
Trial Updated:
07/19/2024
Locations: University of Tennessee Health Science Center, Memphis, Tennessee
Conditions: Post Operative Pain
Using Ultrasound Elastography to Predict Development of Hepatic Sinusoidal Obstruction Syndrome
Recruiting
To perform an receiver operating characteristic (ROC) analysis, define a threshold and quantify the sensitivity and specificity of US SWE for risk stratification of patients into three categories as defined by the European Bone Marrow Transplant (EBMT) adult and pediatric criteria: no sinusoidal obstruction syndrome (SOS), mild to moderate SOS, and severe to very severe SOS. Secondarily, the investigators would also like to quantify the temporal relationship between US SWE changes and SOS diagno... Read More
Gender:
ALL
Ages:
Between 1 month and 99 years
Trial Updated:
07/16/2024
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Bone Marrow Transplant Complications, Sinusoidal Obstruction Syndrome, Veno Occlusive Disease, Hepatic, Stem Cell Transplant Complications
PARADIGM: Amplatzer Valvular Plug for PVL Closure
Recruiting
The Paradigm study is a prospective, multicenter, single arm study to demonstrate the safety and effectiveness of the Amplatzer Valvular Plug III (AVP III) as a treatment for clinically significant PVLs following surgical implant of a mechanical or biological heart valve implanted in the aortic or mitral position.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/11/2024
Locations: Baptist Memorial Hospital, Memphis, Tennessee
Conditions: Paravalvular Aortic Regurgitation